APhA depression management study
Executive Summary
American Pharmacists Association is launching a depression-management program to evaluate the effect of pharmacist-delivered medication therapy management-type services. Project ImPACT: Depression (Improving Persistence And Compliance with Therapy) will focus on whether pharmacists can improve depression treatent adherence. Project ImPACT has previously targeted hyperlipidemia and osteoporosis (1"The Pink Sheet" March 30, 1998, p. 20). Support for the depression study is provided by Wyeth, manufacturer of the serotonin/norepinephrine reuptake inhibitor Effexor XR (venlafaxine extended-release)...
You may also be interested in...
Mevacor-to-Lescol Switches Should Encourage Lescol 40 mg - Study
Programs to substitute Novartis' Lescol (fluvastatin) for Merck's Mevacor (lovastatin) should consider using only the 40 mg dose of Lescol to avoid a significant worsening of outcomes, a study of one switch program concluded.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.